Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

Authors:

Abstract
Introduction: Belamaf, a first-in-class B-cell maturation antigen-targeting antibody-drug conjugate (BCMA ADC) approved for the treatment of RRMM, demonstrated